Research Library / Wellness & Immune
Approved outside U.S.

Thymosin Alpha-1

Originally isolated from thymus tissue. It is approved in a number of countries outside the U.S. as an immune therapy.

Quick chart

Change these and every table below updates.

Concentration5 mg/mL
FrequencyTwice weekly
Schedule length6–12 months (label)
Storage after mixing2–8 °C, 28 days

Dosing schedules (as studied)

The Zadaxin® label, approved for chronic hepatitis B in several countries outside the U.S., gives a single regimen: 1.6 mg twice a week for 6 to 12 months. The 6-month course is shown.

Label regimen

Approved outside U.S.

1.6 mg injected under the skin twice a week. Patients under 40 kg receive 40 mcg/kg instead.

PhaseWeeksDose per injectionSyringe unitsVolumeDoses per vial*
Treatment1–26 1.6 mg 320.32 mL6

* Limited by the vial's contents or the 28-day use limit after mixing, whichever comes first.

The label specifies injection under the skin only, not into a vein.

Supplies for this schedule (6 months)
  • 9 × 10 mg vials (each vial is used for at most 28 days after mixing)
  • 18 mL bacteriostatic water (2 mL per vial)
  • 52 × 0.5 mL (50-unit) U-100 insulin syringes
  • 113 alcohol prep pads, plus a sharps container
Shop handling supplies on Amazon →

Reconstitution for this setup

  1. Let the 10 mg vial reach room temperature and wipe both stoppers with alcohol.
  2. Slowly add 2 mL of bacteriostatic water, aiming down the inside wall of the vial.
  3. Swirl gently until clear. Never shake.
  4. Label the vial: 5 mg/mL, with today's date. Refrigerate and use within 28 days.

Label details

UseDoseScheduleDuration
Chronic hepatitis B (adults)1.6 mgTwice weekly, injected under the skin6 to 12 months
  • The label specifies injection under the skin only, not into a vein.
  • Patients under 40 kg receive a weight-based dose instead (40 mcg per kg).

Research summary

Thymosin alpha-1 helps regulate T-cell function. A synthetic version, thymalfasin, is approved in a number of countries for chronic hepatitis B and C and as an immune support in some cancer treatments.

What the research shows

  • It has decades of clinical use outside the U.S. with a generally favorable safety record.
  • Studies in sepsis and COVID-19 had mixed results.
  • It is not FDA approved in the United States.

References

  1. Zadaxin® (thymalfasin) product information, Singapore Health Sciences Authority. View source
  2. Zadaxin drug information, RxList. View source

Related compounds

Last reviewed: November 2026

This page reports what published research and official labels describe. It isn't a recommendation to use any compound. Decisions about any compound should be made with a licensed clinician.